[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 14, Issue 2 (Iranian South Medical of Journal 2011) ::
Iran South Med J 2011, 14(2): 122-133 Back to browse issues page
Neuroendocrine tumors treatment with I-131 Metaiodobenzylguanidine (MIBG)
Armaghan Fard-fahani1, Davood Beiki 2, Babak Fallahi1, Alireza Emami-Ardakani1, Mohsen Saghari1, Mohammad Eftekhary1
1- Tehran University of Medical Sciences
2- Tehran University of Medical Sciences , beikidav@sina.tums.ac.ir
Abstract:   (18080 Views)

Background: I-131 Metaiodobenzylguanidine (MIBG) is a radiopharmaceutical which is proved effective in treatment of tumors with neuroendocrine origin, especially the neuroectodermal (sympathoadrenal) type, including pheochromocytoma, paraganglioma and neuroblastoma. It is also of some value in other neuroendocrine tumors (mainly carcinoid and medullary carcinoma of thyroid). Methods: The method employed in this research was a systematic bibliographic review, in which only valid studies or the clinically detailed enough open-labeled studies using validated scales were used. Results: I-131 MIBG is the best nonsurgical method for treatment of pheochromocytoma. It not only increases survival, but also significantly improves patients’ symptoms (75-90%). Although the efficacy of this method for refractory or relapsing neuroblastoma has been 30%, adding other treatment modalities increases the impact of this treatment. For other neuroendocrine tumors including carcinoid tumor and medullary carcinoma of thyroid, MIBG therapy has been effective in reducing patients’ symptoms. The most important complication of this method is myelosuppression which needs follow-up and if necessary relevant treatment. Conclusion: I-131 MIBG has an important role in treatment of chromafin tumors. For pheochromocytoma and neuroblastoma it is the best nonsurgical treatment. It is effective in neuroblastoma especially if it is used in conjunction with other treatment modalities. I-131 MIBG can also diminish symptoms of carcinoid tumor and medullary thyroid carcinoma efficiently.

Keywords: pheochromocytoma, neuroblastoma, I-131 MIBG, carcinoid tumor, medullary thyroid carcinoma, neuroendocrine tumors
Full-Text [PDF 222 kb]   (1593 Downloads)    
Type of Study: Original | Subject: General
Received: 2011/03/16 | Accepted: 2011/03/16 | Published: 2011/03/16
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Fard-fahani A, Beiki D, Fallahi B, Emami-Ardakani A, Saghari M, Eftekhary M. Neuroendocrine tumors treatment with I-131 Metaiodobenzylguanidine (MIBG). Iran South Med J. 2011; 14 (2) :122-133
URL: http://ismj.bpums.ac.ir/article-1-259-en.html


Volume 14, Issue 2 (Iranian South Medical of Journal 2011) Back to browse issues page
دانشگاه علوم پزشکی بوشهر، طب جنوب ISMJ

Iranian South Medical Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License which allows users to read,
copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly

Copyright © 2017, Iranian South Medical Journal| All Rights Reserved

Persian site map - English site map - Created in 0.06 seconds with 32 queries by YEKTAWEB 3921